DiannaSueHowardMD

PubMed

• High-dimensional Immune Profiles and Machine Learning May Predict Acute Myeloid Leukemia Relapse Early following Transplant.
  Samantha M Short, Mildred D Perez, Alexis E Morse, Rebecca Damron Jennings, Dianna S Howard
  Journal of Immunology. 2024-11-15
• Real-World Analysis of Barriers to Timely Administration of Chimeric Antigen Receptor T Cell (CAR T) Therapy in Diffuse Large B-cell Lymphoma.
  Bei Hu, Rakhee Vaidya, Ferdous Ahmed, Hamid Ehsan, Tamara K Moyo
  Transplantation and Cellular Therapy. 2024-11-01
• In Pursuit of Optimal Outcomes: A Framework for Quality Standards in Immune Effector Cell Therapy.
  Christopher E Dandoy, Joan Adams, Andrew Artz, Christopher Bredeson, Parastoo B Dahi
  Transplantation and Cellular Therapy. 2024-10-01

Journal Articles

• Final Outcomes of Escalated Melphalan 280 mg/m2 with Amifostine Cytoprotection Followed Autologous Hematopoietic Stem Cell Transplantation for Multiple Myeloma: High C...  
  Neal Flomenberg, Dianna S Howard, Barry R Meisenberg, Parameswaran Hari, Gordon L Phillips, David H Vesole, Jasleen Randhawa, Aaron P Rapoport, Nature
• Age Adjusted Hematopoietic Stem Cell Transplant Comorbidity Index Predicts Survival in a T-cell Depleted Cohort☆  
  Swati Yalamanchi, Hayder Saeed, Dianna Howard, Gerhard C Hildebrandt, Roger Herzig, Gregory Monohan, ScienceDirect
• Concomitant Renal Cell Carcinoma and Hematologic Malignancy in Immunosuppressed Patients  
  L Johnson, J Bylund, S Strup, DS Howard, Z Gul, MW Khan, R Venkatesh, Am Jrnl Med Sci, 1/1/2016
• Simultaneous Quantitation of Oxidized and Reduced Glutathione via LC-MS/MS: An insight into the redox state of hematopoietic stem cells  
  D Carroll, DS Howard, H Zhu, C Paumi, M Vore, S Bondada, Y Liang, C Wang and DK St.Clair, Free Rad Biol Med, 1/1/2016
• Genetics of CD33 in Alzheimer's Disease and Acute Myeloid Leukemia  
  M Manasi, J Chiles, HS Xi, C Medway, J Simpson, S Potluri, DS Howard, Y Liang, CM Paumi, S Mukherjee, P Crane, S Younkin, DW Fardo, and S Estus, Human Molecular Genetics, 1/1/2015
• A Phase 2 study of Bortezomib Combined with either Idarubicin/Cytarabine or Cytarabine/Etoposide in Children with Relapsed, Refractory or Secondary Acute Myeloid Leuke...  
  TM Horton, JP Perentesis, AS Gamis, TA Alonzo, RB Gerbing, J Ballard, K Adlard, DS Howard, FO Smith, G Jenkins, A Kelder, G Schuurhuis and J A Moscow, Pediatr Blood Cancer, 1/1/2014
• A Phase II Trial of Azacitidine and Gemtuzumab Ozogamicin Therapy in Older Patients with Acute Myeloid Leukemia  
  S Nand, M Othus, JE Godwin, C Willman, TH Norwood, DS Howard, SE Coutre, HP Erba, and FR Appelbaum, Blood, 1/1/2013
• Phase I study using Bortezomib with Weekly Idarubicin for the Treatment of Elderly (> 60 years) and Relapsed Patients with Acute Myeloid Leukemia (AML)  
  DS Howard, J Liesveld, GL Phillips, ML Guzman, and CT Jordan, Leukemia Research, 1/1/2013
• Informed Consent for Chemotherapy: ASCO Member Resource  
  C Storm, J Casillas, H Grunwald, D Howard, K McNiff, and M Neuss, Jrnl of Oncol Practice, 1/1/2009
• Fatal Rhizopus Pneumonia In Allogeneic Stem Cell Transplant Patients Despite Posaconazole Prophylaxis: Two Cases And Review Of The Literature  
  LJ Lekakis, A Lawson, J Prante, J Ribes, GJ David, G Monohan, IG Baraboutis, AT Skoutelis, and DS Howard, Biology of Blood and Marrow Transplant, 1/1/2009
• BK virus nephropathy after allogeneic stem cell transplantation: A case report and literature review  
  LJ Lekakis, V Macrinici, IJ Baraboutis, B Mitchell, and DS Howard, Am Jrnl of Hematology, 1/1/2009
• Medical Futility: Withdrawing medically futile treatment  
  DS Howard and T Pawlik, Jrnl of Oncol Practice, 1/1/2009
• Preferential Loss of Mismatch Repair Function in Refractory and Relapsed Acute Myeloid Leukemia: Potential Contribution to AML Progression  
  G Mao, F Yuan, K Absher, CD Jennings, DS Howard, CT Jordan, and L Gu, Cell Research, 1/1/2008
• Misdiagnosis: Disclosing a colleague’s error  
  Grunwald, DS Howard, M McCabe, and M Rodriguez, Jrnl of Oncol Practice, 1/1/2008
• Amifostine and Autologous Hematopoietic Stem Cell Support of Escalating-Dose Melphalan: A Phase I Study  
  GL Phillips, B Meisenberg, DE Reece, VR Adams, A Badros, J Brunner, R Fenton, J Filicko, D Grosso, GA Hale, DS Howard, VP Johnson, A Kniska, KW Marshall, R Nath, E Ree..., Biology of Blood and Marrow Transplant, 1/1/2004
• Activity of single-agent melphalan 220-300 mg/m2 with amifostine cytoprotection and autologous hematopoietic stem cell support in non-Hodgkin and Hodgkin lymphoma  
  Phillips GL, Meisenberg BR, Reece DE, Adams VR, Badros AZ, Brunner JL, Fenton RG, Filicko J, Grosso DL, Hale GA, Howard DS, Johnson VP, Kniska A, Marshall KW, Mookerje..., Bone Marrow Transplant, 1/1/2004
•  
  JS Thompson, C Pomeroy, RJ Kryscio, SA Brown, DE Reece, RK Kramer, DS Howard, G vanZant, S Humphries and GL Phillips., Biology of Blood and Marrow Transplant, 1/1/2004
• Use of the Anti-idiotype breast cancer vaccine 11D10 in conjunction with autologous stem cell transplantation in patients with metastatic breast cancer  
  Reece DE, Foon DA, Battarchaya-Chatterjee M, Adkins DA, Broun ER, Connaghan DG, Dipersio JF, Holland K, Howard DS, Hale GA, Klingemann HG, Munn RK, Raptis A, and Phill..., Clin Breast Cancer, 1/1/2003
• Interim analysis of the use of the anti-idiotype breast cancer vaccine 11D10 (TriAb) in conjunction with autologous stem cell transplantation in patients with metastat...  
  Reece DE, Foon KA, Battacharya-Chatteriee M, Adkins D, Broun ER, Connaghan DG, Dipersio JF, Holland HK, Howard DS, Hale GA, Klingemann HG, Munn RK, Raptis A, and Phill..., Clin Breast Cancer, 1/1/2001
• F-kB is Constituitively Activated in Primitive Human Acute Myelogenous Leukemia Cells  
  Guzman ML, Upchurch D, Neering SJ, Howard DS, Rizzieri DA, Luger SM, and Jordan CT, Blood, 1/1/2001
• Expression of Tumor Suppressor Genes IRF-1 and DAP-kinase in Primitive Acute Myelogenous Leukemia Cells  
  Guzman ML, Upchurch D, Grimes B, Howard DS, Rizzieri DA, Luger SM, Phillips GL, and Jordan CT, Blood, 1/1/2001
• Red Blood Cell Antigen Changes in Malignancy  
  Winters JL and Howard DS, Immunohematology, 1/1/2001
• Use of the anti-idiotype antibody vaccine TriAb after autologous stem cell transplantation in patients with metastatic breast cancer  
  Reece DE, Foon KA, Bhattacharya-Chatterjee M, Hale GA, Howard DS, Munn RK, Nath R, Plummer BA, Teitelbaum A, and Phillips GL, Bone Marrow Transplant, 1/1/2000
• G-CSF Primed Autologous Marrow Harvest and Transplantation in Cytapheresis “Mobilization Failure” Patients: A Descriptive Analysis  
  Phillips GL, Hale GA, Howard DS, Nath R, Munn RK, Marshall KW, Reece DE, Reed E, and Van Zant G, Hematology, 1/1/2000
• The Interleukin-3 Receptor Alpha Chain is a Unique Marker for Human Acute Myelogenous Leukemia Stem Cells  
  Jordan CT, Upchurch D, Szilvassy SJ, Guzman M, Howard DS, Meyerrose T, Rossi R, Grimes G, Rizzieri DA, Luger SM, and Phillips GL, Leukemia, 1/1/2000
• Join now to see all

Books/Book Chapters

• Clinicians Pocket Drug Reference 
  Chapter: Blood Component Therapy 
  Editors: Howard DS, Gomella LG, Haist S, Adams AG, and Smith KM.The McGraw-Hill Companies, Inc.Edition 11th,2005
• Internal Medicine On-Call 
  Chapter: Anemia 
  Editors: Howard DS, Haist S, Robbins JB, and Gomella LG.McGraw-Hill Medical PublisherEdition 4th,2002
• Internal Medicine On-Call 
  Chapter: Polycythemia 
  Editors: Howard DS, Haist S, Robbins JB, and Gomella LG.McGraw-Hill Medical PublisherEdition 4th,2002

Abstracts/Posters

• Selinexor in Combination with Induction and Consolidation Therapy in Older Adults with AML Is Highly ActiveClinically Relevant Abstract
  Dianna S. Howard, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Evaluating the Utilization of All-Trans Retinoic Acid and Arsenic Trioxide during Consolidation Therapy for Patients Receiving Treatment for Acute Promyelocytic Leukemia
  Dianna S. Howard, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• The Mitochondrial Metabolism Inhibitor CPI-613 in Combination with High Dose Ara-C (HiDAC) and Mitoxantrone is Highly Active in High Risk Relapsed or Refractory Acute ...
  Pardee TS, Pladna K, Isom S, Ellis LR, Berenzon D, Hurd DH, Howard DS, Harrelson R, Manuel M, Dralle S, Lyerly S, and Powell BL, American Society Clinical Oncology Meeting, Chicago, IL, 1/1/2015
• phase II trial of Azacitidine (NSC-102816) and Gemtuzumab Ozogamicin (NSC-720568) as induction and post-remission therapy in patients of age 60 and older with previous...
  Nand S, Gundacker H, Godwin JE, Willman CL, Norwood TH, Erba HP, Howard DS, Coutre SE, Othus M, and Appelbaum FR, American Society of Hematology Meeting, Atlanta, GA, 1/1/2012
• phase II trial of Azacitidine (NSC-102816) and Gemtuzumab Ozogamicin (NSC-720568) as induction and post-remission therapy in patients of age 60 and older with previous...
  Nand S, Gundacker H, Godwin JE, Willman CL, Norwood TH, Erba HP, Howard DS, Coutre SE, Othus M, and Appelbaum FR, American Society of Clinical Oncology, Chicago, IL, 1/1/2012
• Chemotherapy-induced skin changes masquerading as squamous cell carcinoma in-situ in a post-bone marrow transplant patient
  Rosser J, Arora R, Patel R, Cibull ML, Howard DS, and Karabakhtsian RG, American Society Clinical Pathology, Boston, MA, 1/1/2012
• A phase 2 study of bortezomib combined with reinduction chemotherapy in children and young adults with recurrent, refractory or secondary acute myeloid leukemia: A Chi...
  Horton TM, Perentesis J, Gamis A, Alonzo TA, Gerbing RB, Wallas T, Francisco L, Ballard J, Adlard K, Howard DS, Smith FO, and Moscow JA, American Society of Hematology Meeting, Atlanta, GA, 1/1/2012
• MRP1 plays a role in regulating hematopoietic stem cell oxidative stress and differentiation via MRP1-dependent GSH efflux
  Reiling C, Howard DS, and Paumi CA., American Society of Hematology Meeting, Atlanta, GA, 1/1/2012
• Intermediate-dose cyclophosphamide (1.5 Gm/M2) with G-CSF as the primary peripheral blood progenitor mobilization strategy: A single institution experience
  Padmanabhan A, Hayslip J, Monohan G, Sutphin S, Weiss H, and Howard DS, American Society of Clinical Oncology, Chicago, IL, 1/1/2011
• In Vitro and Ex Vivo Anti-Leukemia Activity Of AR-67, A Novel Lipophilic Amptothecin
  Tsakalozou E, Howard DS, Leggas M, American Association of Cancer Research, Orlando, FL, 1/1/2011
• Use of Alemtuzumab as Graft-versus-Host Disease Prophylaxis in Myeloablative Unrelated Donor Transplants
  Young K , Lekakis L and Howard DS, American Society Clinical Oncologists Meeting, Chicago, IL, 1/1/2008
• Phase I study using Bortezomib with Weekly Idarubicin for the Treatment of Elderly (> 60 years) and Relapsed Patients with Acute Myeloid Leukemia (AML)
  Howard DS, Liesveld J, Phillips GL, Guzman ML, and Jordan CT, American Society of Hematology Meeting, San Francisco, CA, 1/1/2008
• Preferential apoptosis of primary AML cells in response to Bortezomib and Idarubicin
  Howard DS, Guzman ML, Swiderski CF, and Jordan CT, American Association of Cancer Research, Washington, DC, 1/1/2003
• Guzman ML, Swiderski CF, Rossi RM, Grimes BA, Howard DS, Szilvassy SJ, and Jordan CJ, American Society of Hematologists, Philadelphia, PA, 1/1/2002
• Intensive therapy with high-dose melphalan (MEL) 280mg/m2 plus amifostine cytoprotection and ASCT as part of initial therapy in patients with multiple myeloma
  Reece DE, Vesole D, Flomenberg N, Badros A, Filicko J, Herzig RH, Howard DS, Johnson V, Meisenberg B, Rapoport, Xun CQ, and Phillips GL, American Society of Hematologists, Philadelphia, PA, 1/1/2002
• The treatment of patients with poor prognosis myeloid leukemias using high-dose cytarabine and mitoxantrone with amifostine chemoprotection
  Howard DS, Reece DE, Herzig RH, Gulley CA, Plummer B, and Phillips GL, American Society Clinical Oncologists Meeting, Orlando, FL, 1/1/2002
• Amifostine (AF) cytoprotection of escalating doses of melphalan (MEL) and autologous hematopoietic stem cell transplantation (AHSCT): Final results of a phase I & II s...
  Phillips GL, Meseinberg B, Hale GA, Howard DS, Munn RK, Marshall KW, Nath R, Adams VR, Kniska A, Reece DE, Flomenberg N, Filicko J, and Vesole D, American Society Clinical Oncologists meeting, San Francisco, CA, 1/1/2001
• Failure of Ribavirin in the Treatment of Adenovirus Infections in Hemotopoietic Stem Cell Transplant (HSCT) Recipients
  Howard DS, Harper RM, Phillips DL, Reece DE, Martin C, Rayens, MK, and Pomeroy C, American Society of Hematologists, Orlando, FL, 1/1/2001
• Adenoviruses in Blood and Marrow Transplant
  Howard DS, Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, 1/1/2001
• Resistant Acute Myeloid Leukemia Responds to a Novel Diphtheria Toxin/GM-CSF Fusion Protein: Summary of an Ongoing Phase I Trial
  Mone AP, Howard DS, Molnar I, Kreitman RJ, Frankel AE, American Society of Hematologists, San Francisco, CA, 1/1/2000
• Phase I Trial of Fusion Toxin DTGM Containing Human GM-CSF Fused to Truncated Diphtheria Toxin in Adults with Relapsed or Refractory Acute Myelogenous Leukemia (AML)
  Howard DS, Phillips GL, Hall PD, Kreitman RJ, Frankel AE, American Society Clinical Oncologists Meeting, New Orleans, LA, 1/1/2000
• Use of the Anti-idiotype (ID) Antibody (Ab) Vaccine 11D10 (Triab) After Intensive Therapy (IT) and Autologous Blood Stem Cell Transplantation (ASCT) in Patients (Pts) ...
  Reece DE, Foon KA, Chatterjee M, Howard DS, Munn RK, Teitelbaum A, Phillips GL, American Society Clinical Oncologists Meeting, New Orleans, LA, 1/1/2000
• Gene Transfer in Primary Acute Myeloid Leukemia Cells Utilizing Novel Method
  Howard DS, Grimes BA, Upchurch DT, Rizzieri DA, Phillips GL, Jordan CT, American Society Clinical Oncologists Meeting, New Orleans, LA, 1/1/1999
• Adenoviral Infections Following Bone Marrow Transplantation
  Howard DS, Phillips GL, Reece DE, Pomeroy C, Munn RK, Flett M, American Society Clinical Oncologists Meeting, Los Angeles, CA, 1/1/1998
• Atypical Presentation of Twins with Ornithine Transcarbamylase Deficiency
  Howard DS, Desai NS, Auer JML, Skinker DM, Southern Society of Pediatric Research Meeting, New Orleans, LA, 1/1/1995
• Join now to see all

Lectures

• Therapeutic Manipulation of Cancer Cell Metabolism with the Mitochondrial Metabolism Inhibitor Cpi-613 in Addition to Chemotherapy Abrogates the Adverse Prognostic Eff... 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• BMT Program Overview 
  Wake Forest Comprehensive Cancer Center, Winston-Salem, NC - 1/1/2015
• Updates in the Management of AML 
  The Solution Center, Durham, NC - 1/1/2015
• Optimal Management of AML 
  The Ballantyne Hotel, Charlotte, NC - 1/1/2015
• Transplant Indications and Outcomes – Optimal Timing for Referral 
  Highpoint Cancer Center, Highpoint, NC, 2014; Moses Cone Memorial Hospital, Greensboro, NC, 2015; Wa - 1/1/2015
• Challenges in the Treatment of Older Adult AML 
  University of North Carolina, Chapel Hill, NC - 1/1/2013
• Hemophagocytic Lymphohistiocytosis 
  1/1/2011
• Advances in Acute Leukemia 
  Huntington, WV - 1/1/2011
• Updates in the Management of Acute Leukemias 
  Ashland, KY - 1/1/2008
• Neutropenic Fever in Cancer Patients 
  1/1/2008
• Management of Multiple Myeloma 
  Danville, KY - 1/1/2008
• Decision Making in Pediatric Cancer Patients: a Parent’s Perspective 
  Chicago, IL - 1/1/2007
• Idarubicin Nanoparticles in the Treatment of AML 
  University of Kentucky, Lexington, KY - 1/1/2007
• Advances in Leukemia Research 
  1/1/2007
• Advances in the Management of AML and MDS in the Older Adult 
  University of Kentucky, Lexington, KY - 1/1/2006
• Living with Leukemia 
  Louisville, KY - 1/1/2006
• Velcade and Idarubicin in the Treatment of AML 
  University of Kentucky, Lexington, KY, 2005; University of Kentucky, Lexington, KY, 2006 - 1/1/2006
• Supportive Management of AML Patients 
  Hospice of the Bluegrass, Lexington, KY - 1/1/2006
• AML/MDS in the Elderly 
  Embassy Suites, Lexington, KY - 1/1/2005
• A Novel Therapy in the Treatment of AML 
  University of Kentucky, Lexington, KY - 1/1/2005
• Advances in the Treatment of Acute Myeloid Leukemia 
  Louisville, KY - 1/1/2005
• Novel Therapy in the Treatment of Elderly and Relapsed Acute Myelogenous Leukemia 
  University of Rochester, Rochester, NY - 1/1/2004
• A Review of Acute and Chronic Leukemias 
  Lexington, KY - 1/1/2003
• Preferential Apoptosis of Primary AML Cells in Response to Bortezomib and Idarubicin 
  University of Kentucky, Lexington, KY - 1/1/2003
• Immunochemotherapy in Relapsed AML: Targeted vs. Nonspecific Treatment 
  Lexington, KY - 1/1/2002
• Join now to see all

Other

• Leukemia and Lymphoma Annual Report 
  Howard DS, Kentucky Cancer Registry. University of Kentucky, Markey Cancer Center
  1/1/2003
• Adenoviral Infections in Recipients of Hematopoietic Stem Cell Transplant 
  Howard DS, Infections in Oncology, Physicians’ Education Resource Publishing
  1/1/1998
• Transduction of Primitive Hematopoietic Cells with Adenovirus-polycation Gene Transfer Vehicles: New Strategies for the Management of Hematologic Disease. Autologous M... 
  Jordan CT, Howard DS, Zhao SF, Yannelli JR, Grimes B, Proceedings of the Ninth International Symposium, Carden Jennings Publishing
  1/1/1998